Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis

• Status: Completed
• Trial end date: 2017-07-03
• Target enrollment: 0
• Participant gender: All

Summary

Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stallergenes; Stallergenes Greer
• Collaborator: Venn Life Sciences

Criteria

Inclusion Criteria:

Allergen immunotherapy naive male or female outpatients aged 5 to 9 years (inclusive) prescribed ORALAIR.

Exclusion Criteria:

Patients already participating in a clinical trial.